Burak Finance
Head of Analytics, Growth Investor, PLTR/NBIS/RKLB
Tempus AI's $1.5B all-stock acquisition of Personalis is smart long-term positioning despite the dilution-driven dip. Owning Personalis's NeXT Personal MRD technology outright lets Tempus pair liquid-biopsy recurrence testing, one of oncology's fastest-growing areas, with its multimodal dataset and AI at scale. That extends Tempus from diagnostics into high-margin longitudinal monitoring and could strengthen its moat, though execution will decide it. x.com
Tempus AI offers great risk/reward as growth and profitability improve together. Q1 revenue rose 36% to $348M, 2026 guidance was raised to $1.59-1.60B with positive EBITDA, and data revenue is growing 40%+ with strong bookings visibility. Gross margins are about 70% with $644M in cash, Nancy Pelosi and Cathie Wood are buying, and the chart shows a bullish breakout. x.com
Tempus AI's $1.5 billion all-stock acquisition of Personalis strengthens its position in precision oncology, adding Personalis' MRD platform, expanding its AI-driven diagnostics business and widening its opportunity in a market estimated at about $20 billion. The 6% drop on the news reflects dilution, timing ahead of earnings and near-term integration risk, a classic case of short-term dilution overshadowing long-term strategy. x.com x.com
Tempus AI's Personalis acquisition is a great strategic fit but raises the risk profile, because Tempus overpaid. Personalis adds longitudinal molecular-response and patient-outcome data that reinforce Tempus's data moat. But at roughly 19 times Personalis's guided 2026 revenue, with 15-20% gross margins and about $100M of cash burn, it adds burn on top of Tempus's own and could take years to become accretive. The thesis needs many years of patience and near-flawless execution. x.com x.com
Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com
The new licenses strengthen Tempus AI's long-term $50-100B bull case by monetizing its clinical data in neurology as well as oncology. Per Tempus, Pathos agreed to pay $55M over five years to license a neurology dataset Tempus plans to build from hundreds of thousands of patient records. Tempus also says Bristol Myers Squibb expanded oncology data licensing through 2031 and will gain access to Lens. x.com x.com x.com
Tempus AI's growth story has become a real one, with Q2 revenue up 22% to $382.5 million, positive net income and EBITDA, a 73.5% gross margin and $816 million of cash. Its $1.5 billion Personalis deal owns the sequencing technology behind the Moderna-Merck mRNA cancer vaccine, whose strong Phase 3 melanoma results validated the bet. Piper Sandler upgraded it to Overweight with a $76 target, up from $56, citing Personalis and strong INTerpath-001 MRD data. $80 is support for the breakout. x.com
Tempus AI may go lower near term because of valuation, leadership reputation and insider selling, despite an amazing business. With about 25% growth expected and profitability uncertain, it is not obviously cheap. Glassdoor reviews matter in medicine's high-trust setting, and ongoing insider sales echo founder patterns that ended badly. The data piece, about 5% of market cap, can earn a high multiple, so the stock looks reasonably priced if adoption continues. x.com
Tempus AI's Moderna and Merck collaboration puts its oncology data and algorithms to work on cancer vaccines and immuno-oncology drugs, supporting the commercial value of its pharma data platform. The multiyear agreement adds to its licensing case; Q2 revenue rose more than 21.6% to $382 million, and the EPS loss of $0.04 beat the expected $0.20 loss. Sustained profitability remains prospective. Tempus AI could reach $145. x.com
Tempus AI is becoming a bigger health-tech player as pharma deals add a new services revenue stream beyond selling tests. BTIG's Mark Massaro raised his target to $80 from $70 with a Buy rating, mainly because Tempus will be the sequencing provider for Moderna and Merck's cancer vaccine program. The Personalis deal and MRD momentum add to a strengthening long-term AI and precision-oncology story, despite near-term volatility. x.com
Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.com
Tempus AI's acquisition of Personalis gives it the technology platform behind Moderna's and Merck's recent cancer-vaccine advances. x.com
